The overuse of antibiotics has created strains of bacteria resistant to medication, making the diseases they cause difficult to treat, or even deadly.
At the annual Society for Laboratory Automation and Screening (SLAS) meeting Hamilton Robotics has announced a partnership with Coastal Genomics to launch the new Microlab NIMBUS Select workstation with Ranger Technology.
The rate of usage of disposables in biopharmaceutical manufacturing has increased substantially over the past six years in a variety of areas, but most notably for complex devices, that are also among the most expensive. By Eric Langer
This application note describes the rapid development of a production process for a biosimilar molecule expressed in E. coli. Screening of modern chromatography media for downstream purification was done either with small packed columns and an ÄKTA avant system or with PreDictor plates (96-well pre-filled filter plates).
The routine application of human pluripotent stem cells and their derivatives in regenerative medicine and innovative drug discovery will require the constant supply of high cell numbers in consistent, high quality. By Ruth Olmer, Christina Kropp, Claudia Huether-Franken, Christiane Schlottbom, and Robert Zweigerdt
It is widely understood that the production phase of bioprocessing can have a significant impact on the overall profitability of the biopharmaceutical.
This application note describes the cultivation of CHO suspension cells in the wave-mixed single-use Finesse SmartRocker bioreactor with a maximum working volume of 5 L. Using a chemically defined minimal medium, it was possible to produce up to 16.4∙106 cells∙mL-1. SEAP expression was induced by medium exchange and a temperature shift. Maximum SEAP activity of up 33.1 U∙mL-1 was achieved. The results are comparable to cultivations in other wave-mixed bioreactor types. By Nadezda Perepelitsa, Stephan C. Kaiser and Dieter Eibl
The ÄKTA™ pcc 75 chromatography system can be used for purification of target proteins in continuous downstream processes using periodic counter-current chromatography (PCC). PCC enables greater utilization of the chromatography medium (resin) capacity, allowing sample loading to much higher levels compared with what is possible in traditional batch chromatography.
Implementing an optimized feed medium may be the most effective alternative for modifications to the growth medium in an existing process.
America's biopharmaceutical companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).
Research peptides are used around the world for a number of reason but most notably to test the effects of growth hormone related hormones and growth hormone related peptides and their effects.
Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today provided an overview on the early breast cancer competitive status of the lead cancer immunotherapy product, AE37, under development at its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com).
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed a non-exclusive license agreement with Amgen Inc. for access to DSM's proprietary XD® high cell density process patents.
BioInvent International AB recently announced that Svein Mathisen has resigned from his positions as chief executive officer of the Company and as member of the Board of Directors.
Glen Allen, VA /PRNewswire/ - Star Scientific, Inc. (NASDAQ: STSI) announced today the preliminary results of the Company's ASAP (Anatabloc Supplementation Autoimmune Prevention) Human Thyroid Study that analyzes the impact of anatabine dietary supplementation on thyroid health.
Gradalis, Inc. today announced that is has closed a $24 million Series B round of financing. Gradalis will use the funding to advance its autologous vaccine platform, FANG™, through late-stage clinical trials and expand manufacturing capabilities to accommodate commercial launch of FANG.
ArmaGen Technologies, Inc., a leader in the delivery of biotherapeutics targeting the central nervous system (CNS), today announced James Callaway , Ph.D. as Chief Executive Office and member of the Board of Directors.